{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:50:16Z","timestamp":1794383416040,"version":"4.9.0"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Genom. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pharmacogenetics can enhance cardiovascular disease (CVD) treatment by tailoring drug therapy to genetic profiles and minimising trial-and-error approaches. Genetic variability influences responses to common CVD drugs, including antiplatelet drugs (clopidogrel and aspirin), anticoagulants (warfarin), statins, and antihypertensives (ACE inhibitors and \u03b2-blockers). Understanding genetic polymorphisms can improve efficacy and safety. Despite this progress, further research is needed to optimise pharmacogenomic applications and advance personalised medicine to improve CVD treatment outcomes.<\/jats:p>","DOI":"10.1038\/s41525-025-00511-6","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T16:30:56Z","timestamp":1752165056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications"],"prefix":"10.1038","volume":"10","author":[{"given":"Ayat","family":"Shorbaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Natesan","family":"Pushparaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayat B.","family":"Al-Ghafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna Siraj","family":"Mira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1925-0424","authenticated-orcid":false,"given":"Mohammad Abdullah","family":"Basabrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Imran","family":"Naseer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4979-701X","authenticated-orcid":false,"given":"Muhammad","family":"Abu-Elmagd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-0409","authenticated-orcid":false,"given":"Sherin","family":"Bakhashab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"511_CR1","unstructured":"https:\/\/world-heart-federation.org\/news\/deaths-from-cardiovascular-disease-surged-60-globally-over-the-last-30-years-report\/ (accessed on 29th April 2024)."},{"key":"511_CR2","first-page":"69","volume":"58","author":"H Saunders","year":"2020","unstructured":"Saunders, H., Harris, D. & Chiril\u0103, R. M. Pharmacogenomics: introduction and use in clinical practice. Rom. J. Intern. Med. 58, 69\u201374 (2020).","journal-title":"Rom. J. Intern. Med."},{"key":"511_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev-pharmtox-051921-092701","volume":"63","author":"M Castrichini","year":"2023","unstructured":"Castrichini, M., Luzum, J. A. & Pereira, N. Pharmacogenetics of antiplatelet therapy. Annu. Rev. Pharmacol. Toxicol. 63, 211\u2013229 (2023).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"511_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/17512433.2021.1927709","volume":"14","author":"M Galli","year":"2021","unstructured":"Galli, M. et al. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Rev. Clin. Pharmacol. 14, 963\u2013978 (2021).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"511_CR5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3390\/antiox12061185","volume":"12","author":"L Falco","year":"2023","unstructured":"Falco, L. et al. Antioxidant properties of oral antithrombotic therapies in atherosclerotic disease and atrial fibrillation. Antioxidants 12, 1185 (2023).","journal-title":"Antioxidants"},{"key":"511_CR6","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/molecules26071987","volume":"26","author":"MA Akkaif","year":"2021","unstructured":"Akkaif, M. A. et al. The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD). Molecules 26, 1987 (2021).","journal-title":"Molecules"},{"key":"511_CR7","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.clinthera.2019.04.037","volume":"41","author":"M Saiz-Rodr\u00edguez","year":"2019","unstructured":"Saiz-Rodr\u00edguez, M. et al. Influence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention. Clin. Ther. 41, 1199\u20131212.e1192 (2019).","journal-title":"Clin. Ther."},{"key":"511_CR8","doi-asserted-by":"publisher","first-page":"e002436","DOI":"10.1136\/openhrt-2023-002436","volume":"10","author":"J Lopez","year":"2023","unstructured":"Lopez, J. et al. Role of genetic polymorphisms in clopidogrel response variability: a systematic review. Open Heart 10, e002436 (2023).","journal-title":"Open Heart"},{"key":"511_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","volume":"112","author":"CR Lee","year":"2022","unstructured":"Lee, C. R. et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin. Pharmacol. Ther.112, 959\u2013967 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2217\/pgs-2020-0046","volume":"21","author":"M Ellithi","year":"2020","unstructured":"Ellithi, M., Baye, J. & Wilke, R. A. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics 21, 889\u2013897 (2020).","journal-title":"Pharmacogenomics"},{"key":"511_CR11","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.12659\/MSM.915971","volume":"25","author":"Q Su","year":"2019","unstructured":"Su, Q. et al. Association of CYP2C19 polymorphism with clopidogrel resistance in patients with acute coronary syndrome in China. Med. Sci. Monit.25, 7138 (2019).","journal-title":"Med. Sci. Monit."},{"key":"511_CR12","first-page":"123","volume":"19","author":"Z-l Zhuo","year":"2018","unstructured":"Zhuo, Z. -l. et al. Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. Anatol. J. Cardiol. 19, 123 (2018).","journal-title":"Anatol. J. Cardiol."},{"key":"511_CR13","doi-asserted-by":"publisher","first-page":"3470145","DOI":"10.1155\/2019\/3470145","volume":"2019","author":"W Peng","year":"2019","unstructured":"Peng, W., Shi, X., Xu, X. & Lin, Y. Both CYP2C19 and PON1 Q192R genotypes influence platelet response to clopidogrel by thrombelastography in patients with acute coronary syndrome. Cardiovasc. Ther. 2019, 3470145 (2019).","journal-title":"Cardiovasc. Ther."},{"key":"511_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019143","volume":"99","author":"G Liu","year":"2020","unstructured":"Liu, G., Yang, S. & Chen, S. The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention. Medicine 99, e19143 (2020).","journal-title":"Medicine"},{"key":"511_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85580-0","volume":"11","author":"Y-J Li","year":"2021","unstructured":"Li, Y.-J. et al. Association between CYP2C19 polymorphisms and clinical outcomes in patients undergoing stent procedure for cerebral artery stenosis. Sci. Rep. 11, 5974 (2021).","journal-title":"Sci. Rep."},{"key":"511_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2217\/pgs-2021-0098","volume":"23","author":"M Biswas","year":"2022","unstructured":"Biswas, M., Sukasem, C., Khatun Kali, M. S. & Ibrahim, B. Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Pharmacogenomics 23, 207\u2013220 (2022).","journal-title":"Pharmacogenomics"},{"key":"511_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/09537104.2017.1413178","volume":"30","author":"Z Xi","year":"2019","unstructured":"Xi, Z. et al. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis. Platelets 30, 229\u2013240 (2019).","journal-title":"Platelets"},{"key":"511_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","volume":"121","author":"D Sibbing","year":"2010","unstructured":"Sibbing, D. et al. Cytochrome 2C19* 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121, 512\u2013518 (2010).","journal-title":"Circulation"},{"key":"511_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/ehjcvp\/pvz045","volume":"6","author":"JP Lewis","year":"2020","unstructured":"Lewis, J. P. et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur. Heart J. Cardiovasc. Pharmacother. 6, 203\u2013210 (2020).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"511_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/cpt.2039","volume":"109","author":"CR Lee","year":"2021","unstructured":"Lee, C. R. et al. Impact of the CYP2C19* 17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. Clin. Pharmacol. Ther. 109, 705\u2013715 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR21","first-page":"4195","volume":"17","author":"M Dehbozorgi","year":"2018","unstructured":"Dehbozorgi, M. et al. Prevalence of the CYP2C19* 2 (681 G> A),* 3 (636 G> A) and* 17 (\u2011806 C> T) alleles among an Iranian population of different ethnicities. Mol. Med. Rep. 17, 4195\u20134202 (2018).","journal-title":"Mol. Med. Rep."},{"key":"511_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s002280050497","volume":"54","author":"H Yamada","year":"1998","unstructured":"Yamada, H. et al. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur. J. Clin. Pharmacol. 54, 479\u2013481 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"511_CR23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00008571-199504000-00004","volume":"5","author":"JJ Brockm\u00f6ller","year":"1995","unstructured":"Brockm\u00f6ller, J. J., Rost, K., Gross, D., Schenkel, A. & Roots, I. Phenotyping of CYP2C19 with enantiospecific HPLCquantification of R-and S-mephenytoin and comparison with the intron4\/exon5 G\u2192 A-splice site mutation. Pharmacogenetics 5, 80\u201388 (1995).","journal-title":"Pharmacogenetics"},{"key":"511_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/00008571-199612000-00005","volume":"6","author":"I Persson","year":"1996","unstructured":"Persson, I., Aklillu, E., Rodrigues, F., Bertilsson, L. & Ingelman-Sundberg, M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6, 521\u2013526 (1996).","journal-title":"Pharmacogenetics"},{"key":"511_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s002280100282","volume":"57","author":"C Dandara","year":"2001","unstructured":"Dandara, C. et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east-and southern African populations including psychiatric patients. Eur. J. Clin. Pharmacol. 57, 11\u201317 (2001).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"511_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00008571-199702000-00008","volume":"7","author":"JA Goldstein","year":"1997","unstructured":"Goldstein, J. A. et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59\u201364 (1997).","journal-title":"Pharmacogenetics"},{"key":"511_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/FPC.0b013e32831ebb30","volume":"19","author":"J Sistonen","year":"2009","unstructured":"Sistonen, J. et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics 19, 170\u2013179 (2009).","journal-title":"Pharmacogenet. Genomics"},{"key":"511_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/00008571-199608000-00006","volume":"6","author":"M Jurima-Romet","year":"1996","unstructured":"Jurima-Romet, M. et al. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics 6, 329\u2013339 (1996).","journal-title":"Pharmacogenetics"},{"key":"511_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s002280050487","volume":"54","author":"L Bathum","year":"1998","unstructured":"Bathum, L., Andersen-Ranberg, K., Boldsen, J., Br\u00f8sen, K. & Jeune, B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevity: role of CYP2D6 and CYP2C19 in longevity. Eur. J. Clin. Pharmacol. 54, 427\u2013430 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"511_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0009-9236(98)90070-4","volume":"64","author":"K Herrlin","year":"1998","unstructured":"Herrlin, K. et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin. Pharmacol. Ther. 64, 391\u2013401 (1998).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00228-010-0864-8","volume":"66","author":"RS Pedersen","year":"2010","unstructured":"Pedersen, R. S. et al. Linkage disequilibrium between the CYP2C19* 17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur. J. Clin. Pharmacol. 66, 1199\u20131205 (2010).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"511_CR32","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1046\/j.1365-2125.2002.01604.x","volume":"53","author":"SI Hamdy","year":"2002","unstructured":"Hamdy, S. I. et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol. 53, 596\u2013603 (2002).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"511_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-7364-3-1-17","volume":"3","author":"H-L Hsu","year":"2008","unstructured":"Hsu, H.-L., Woad, K. J., Woodfield, D. G. & Helsby, N. A. A high incidence of polymorphic CYP2C19 variants in archival blood samples from Papua New Guinea. Hum. Genomics 3, 1\u20137 (2008).","journal-title":"Hum. Genomics"},{"key":"511_CR34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.clpt.6100291","volume":"83","author":"I Rudberg","year":"2008","unstructured":"Rudberg, I., Mohebi, B., Hermann, M., Refsum, H. & Molden, E. Impact of the ultrarapid CYP2C19* 17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83, 322\u2013327 (2008).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1124\/dmd.109.030601","volume":"38","author":"GL Kearns","year":"2010","unstructured":"Kearns, G. L., Leeder, J. S. & Gaedigk, A. Impact of the CYP2C19* 17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab. Dispos. 38, 894\u2013897 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"511_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim, S. C. et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103\u2013113 (2006).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2710.2009.01069.x","volume":"35","author":"KA Kim","year":"2010","unstructured":"Kim, K. A., Song, W. K., Kim, K. R. & Park, J. Y. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19* 2, CYP2C19* 3, and CYP2C19* 17 alleles. J. Clin. Pharm. Ther. 35, 697\u2013703 (2010).","journal-title":"J. Clin. Pharm. Ther."},{"key":"511_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-2125.2007.03057.x","volume":"65","author":"K Sugimoto","year":"2008","unstructured":"Sugimoto, K., Uno, T., Yamazaki, H. & Tateishi, T. Limited frequency of the CYP2C19* 17 allele and its minor role in a Japanese population. Br. J. Clin. Pharmacol. 65, 437\u2013439 (2008).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"511_CR39","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00228-006-0183-2","volume":"62","author":"M Kurzawski","year":"2006","unstructured":"Kurzawski, M. et al. Effect of CYP2C19* 17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur. J. Clin. Pharmacol. 62, 877\u2013880 (2006).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"511_CR40","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"Group, E. S. D.","year":"2021","unstructured":"Group, E. S. D. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 42, 1289\u20131367 (2021).","journal-title":"Eur. Heart J."},{"key":"511_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","volume":"14","author":"NL Pereira","year":"2021","unstructured":"Pereira, N. L. et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta analysis. JACC Cardiovasc. Interv.14, 739\u2013750 (2021).","journal-title":"JACC Cardiovasc. Interv."},{"key":"511_CR42","doi-asserted-by":"publisher","first-page":"8703627","DOI":"10.1155\/2020\/8703627","volume":"2020","author":"G Patti","year":"2020","unstructured":"Patti, G., Micieli, G., Cimminiello, C. & Bolognese, L. The role of clopidogrel in 2020: a reappraisal. Cardiovasc. Ther. 2020, 8703627 (2020).","journal-title":"Cardiovasc. Ther."},{"key":"511_CR43","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1161\/CIR.0000000000001257","volume":"150","author":"NL Pereira","year":"2024","unstructured":"Pereira, N. L. et al. CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association. Circulation 150, e129\u2013e150 (2024).","journal-title":"Circulation"},{"key":"511_CR44","doi-asserted-by":"publisher","first-page":"24749","DOI":"10.1074\/jbc.M114.583021","volume":"289","author":"TW Loo","year":"2014","unstructured":"Loo, T. W. & Clarke, D. M. Cysteines introduced into extracellular loops 1 and 4 of human P-glycoprotein that are close only in the open conformation spontaneously form a disulfide bond that inhibits drug efflux and ATPase activity. J. Biol. Chem. 289, 24749\u201324758 (2014).","journal-title":"J. Biol. Chem."},{"key":"511_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/ijerph14030301","volume":"14","author":"Y-J Zhang","year":"2017","unstructured":"Zhang, Y.-J., Li, M.-P., Tang, J. & Chen, X.-P. Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives. Int. J. Environ. Res. Public Health 14, 301 (2017).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"511_CR46","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jamaneurol.2019.2531","volume":"76","author":"Y Pan","year":"2019","unstructured":"Pan, Y. et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE) and platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trials. JAMA Neurol. 76, 1466\u20131473 (2019).","journal-title":"JAMA Neurol."},{"key":"511_CR47","doi-asserted-by":"publisher","first-page":"25684","DOI":"10.18632\/aging.104177","volume":"12","author":"S Zhang","year":"2020","unstructured":"Zhang, S. et al. A SNP involved in alternative splicing of ABCB1 is associated with clopidogrel resistance in coronary heart disease in Chinese population. Aging 12, 25684 (2020).","journal-title":"Aging"},{"key":"511_CR48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/FJC.0000000000000767","volume":"75","author":"J Samardzic","year":"2020","unstructured":"Samardzic, J. et al. Impact of continuous P2Y12 inhibition tailoring in acute coronary syndrome and genetically impaired clopidogrel absorption. J. Cardiovasc. Pharmacol. 75, 174\u2013179 (2020).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"511_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22369","volume":"32","author":"X Hou","year":"2018","unstructured":"Hou, X., Han, W., Gan, Q., Liu, Y. & Fang, W. CYP 2C19 and ABCB 1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. J. Clin. Lab. Anal. 32, e22369 (2018).","journal-title":"J. Clin. Lab. Anal."},{"key":"511_CR50","first-page":"307","volume":"19","author":"S Namazi","year":"2020","unstructured":"Namazi, S. et al. Association of ABCB1 gene polymorphisms and clopidogrel responsiveness in Iranian patients undergoing percutaneous coronary intervention. Iran. J. Pharm. Res.19, 307 (2020).","journal-title":"Iran. J. Pharm. Res."},{"key":"511_CR51","doi-asserted-by":"crossref","unstructured":"Gao, H. et al. Advances and perspectives in methods for identifying high platelet reactivity. Heliyon 9, e22214 (2023).","DOI":"10.1016\/j.heliyon.2023.e22214"},{"key":"511_CR52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1124\/jpet.112.201640","volume":"344","author":"H-J Zhu","year":"2013","unstructured":"Zhu, H.-J. et al. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J. Pharmacol. Exp. Ther. 344, 665\u2013672 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"511_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/bcpt.12916","volume":"122","author":"M Neuvonen","year":"2018","unstructured":"Neuvonen, M. et al. Effects of genetic variants on carboxylesterase 1 gene expression, and clopidogrel pharmacokinetics and antiplatelet effects. Basic Clin. Pharmacol. Toxicol. 122, 341\u2013345 (2018).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"511_CR54","first-page":"20180039","volume":"34","author":"KB Mirzaev","year":"2019","unstructured":"Mirzaev, K. B. et al. Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab. Pers. Ther. 34, 20180039 (2019).","journal-title":"Drug Metab. Pers. Ther."},{"key":"511_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/FPC.0000000000000349","volume":"28","author":"S Fathy","year":"2018","unstructured":"Fathy, S. et al. Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. Pharmacogenet. Genomics 28, 207\u2013213 (2018).","journal-title":"Pharmacogenet. Genomics"},{"key":"511_CR56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nm.2281","volume":"17","author":"HJ Bouman","year":"2011","unstructured":"Bouman, H. J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110\u2013116 (2011).","journal-title":"Nat. Med."},{"key":"511_CR57","doi-asserted-by":"publisher","first-page":"e52779","DOI":"10.1371\/journal.pone.0052779","volume":"8","author":"KW Park","year":"2013","unstructured":"Park, K. W. et al. Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI. PLoS ONE 8, e52779 (2013).","journal-title":"PLoS ONE"},{"key":"511_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-019-0378-7","volume":"21","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z., Chen, M., Zhang, L. & Zhao, Q. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention. BMC Pharmacol. Toxicol. 21, 1\u20139 (2020).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"511_CR59","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.atherosclerosis.2016.07.901","volume":"251","author":"W Ma","year":"2016","unstructured":"Ma, W. et al. Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting. Atherosclerosis 251, 305\u2013310 (2016).","journal-title":"Atherosclerosis"},{"key":"511_CR60","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s11239-015-1264-9","volume":"41","author":"JL Mega","year":"2016","unstructured":"Mega, J. L. et al. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. J. Thromb. Thrombolysis 41, 374\u2013383 (2016).","journal-title":"J. Thromb. Thrombolysis"},{"key":"511_CR61","first-page":"111","volume":"21","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: a cohort study from Han Chinese. J. Res. Med. Sci. 21, 111 (2016).","journal-title":"J. Res. Med. Sci."},{"key":"511_CR62","doi-asserted-by":"crossref","unstructured":"Cui, G., Zhang, S., Zou, J., Chen, Y. & Chen, H. P2Y 12 receptor gene polymorphism and the risk of resistance to clopidogrel: a meta-analysis and review of the literature. Adv, Clin. Exp. Med. 26, 343\u2013349 (2017).","DOI":"10.17219\/acem\/63745"},{"key":"511_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1631\/jzus.B1600333","volume":"18","author":"X-y Nie","year":"2017","unstructured":"Nie, X. -y. et al. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. J. Zhejiang Univ. Sci. B 18, 37 (2017).","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"511_CR64","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019472","volume":"99","author":"H Fu","year":"2020","unstructured":"Fu, H., Hu, P., Ma, C., Peng, F. & He, Z. Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: an observational study. Medicine 99, e19472 (2020).","journal-title":"Medicine"},{"key":"511_CR65","doi-asserted-by":"publisher","first-page":"e6553","DOI":"10.1097\/MD.0000000000006553","volume":"96","author":"M Li","year":"2017","unstructured":"Li, M. et al. Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. Medicine 96, e6553 (2017).","journal-title":"Medicine"},{"key":"511_CR66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/a-0622-8110","volume":"69","author":"K Zhao","year":"2019","unstructured":"Zhao, K. et al. P2Y12 polymorphisms and the risk of adverse clinical events in patients treated with clopidogrel: a meta-analysis. Drug Res. 69, 23\u201331 (2019).","journal-title":"Drug Res."},{"key":"511_CR67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","volume":"388","author":"PM Rothwell","year":"2016","unstructured":"Rothwell, P. M. et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388, 365\u2013375 (2016).","journal-title":"Lancet"},{"key":"511_CR68","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine, G. N. et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 134, e123\u2013e155 (2016).","journal-title":"Circulation"},{"key":"511_CR69","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.3390\/biomedicines10102564","volume":"10","author":"A Ikonnikova","year":"2022","unstructured":"Ikonnikova, A. et al. Genetic association study and machine learning to investigate differences in platelet reactivity in patients with acute ischemic stroke treated with aspirin. Biomedicines 10, 2564 (2022).","journal-title":"Biomedicines"},{"key":"511_CR70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/pgs-2019-0133","volume":"21","author":"M Ferreira","year":"2020","unstructured":"Ferreira, M. et al. The emergent phenomenon of aspirin resistance: insights from genetic association studies. Pharmacogenomics 21, 125\u2013140 (2020).","journal-title":"Pharmacogenomics"},{"key":"511_CR71","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/1076029612444002","volume":"19","author":"X-l Li","year":"2013","unstructured":"Li, X. -l. et al. Genetic polymorphisms of HO-1 and COX-1 are associated with aspirin resistance defined by light transmittance aggregation in Chinese Han patients. Clin. Appl. Thromb. Hemost. 19, 513\u2013521 (2013).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"511_CR72","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jns.2017.03.014","volume":"376","author":"H Cai","year":"2017","unstructured":"Cai, H. et al. Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: interaction with smoking. J. Neurol. Sci. 376, 211\u2013215 (2017).","journal-title":"J. Neurol. Sci."},{"key":"511_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-019-1505-1","volume":"19","author":"L Zhao","year":"2019","unstructured":"Zhao, L. et al. Interaction between COX-1 and COX-2 increases susceptibility to ischemic stroke in a Chinese population. BMC Neurol. 19, 1\u201312 (2019).","journal-title":"BMC Neurol."},{"key":"511_CR74","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2217\/14622416.8.6.577","volume":"8","author":"Q Li","year":"2007","unstructured":"Li, Q. et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 8, 577\u2013586 (2007).","journal-title":"Pharmacogenomics"},{"key":"511_CR75","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1160\/TH08-11-0753","volume":"101","author":"C Pettinella","year":"2009","unstructured":"Pettinella, C. et al. Cyclooxygenase-1 haplotype C50T\/A-842G does not affect platelet response to aspirin. Thromb. Haemost. 101, 687\u2013690 (2009).","journal-title":"Thromb. Haemost."},{"key":"511_CR76","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1161\/01.ATV.0000030340.80207.C5","volume":"22","author":"A Papafili","year":"2002","unstructured":"Papafili, A. et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol. 22, 1631\u20131636 (2002).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"511_CR77","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11239-012-0777-8","volume":"35","author":"V Sharma","year":"2013","unstructured":"Sharma, V. et al. Association of COX-2 rs20417 with aspirin resistance. J. Thromb. Thrombolysis 35, 95\u201399 (2013).","journal-title":"J. Thromb. Thrombolysis"},{"key":"511_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22331","volume":"32","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. Association of GPI a and COX-2 gene polymorphism with aspirin resistance. J. Clin. Lab. Anal. 32, e22331 (2018).","journal-title":"J. Clin. Lab. Anal."},{"key":"511_CR79","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s10072-013-1340-x","volume":"34","author":"J Zhao","year":"2013","unstructured":"Zhao, J. et al. Association of thromboxane A2 receptor gene polymorphisms with cerebral infarction in a Chinese population. Neurol. Sci. 34, 1791\u20131796 (2013).","journal-title":"Neurol. Sci."},{"key":"511_CR80","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/aps.2016.90","volume":"37","author":"L-l Peng","year":"2016","unstructured":"Peng, L. -l. et al. Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Acta Pharmacol. Sin. 37, 1442\u20131448 (2016).","journal-title":"Acta Pharmacol. Sin."},{"key":"511_CR81","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2174\/138161206776361318","volume":"12","author":"RF Storey","year":"2006","unstructured":"Storey, R. F. Biology and pharmacology of the platelet P2Y12 receptor. Curr. Pharm. Des. 12, 1255\u20131259 (2006).","journal-title":"Curr. Pharm. Des."},{"key":"511_CR82","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI20986","volume":"113","author":"RT Dorsam","year":"2004","unstructured":"Dorsam, R. T. & Kunapuli, S. P. Central role of the P2Y 12 receptor in platelet activation. J. Clin. Investig. 113, 340\u2013345 (2004).","journal-title":"J. Clin. Investig."},{"key":"511_CR83","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2125.2008.03183.x","volume":"66","author":"T Goodman","year":"2008","unstructured":"Goodman, T., Ferro, A. & Sharma, P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br. J. Clin. Pharmacol. 66, 222\u2013232 (2008).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"511_CR84","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/ATVBAHA.108.168971","volume":"28","author":"JE Herrera-Galeano","year":"2008","unstructured":"Herrera-Galeano, J. E. et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler. Thrombos. Vasc. Biol. 28, 1484\u20131490 (2008).","journal-title":"Arterioscler. Thrombos. Vasc. Biol."},{"key":"511_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.664012","volume":"8","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Platelet endothelial aggregation receptor 1 polymorphism is associated with functional outcome in small-artery occlusion stroke patients treated with aspirin. Front. Cardiovasc. Med. 8, 664012 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"511_CR86","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2174\/1381612043384682","volume":"10","author":"JF Fullard","year":"2004","unstructured":"Fullard, J. F. The role of the platelet glycoprotein IIb\/IIIa in thrombosis and haemostasis. Curr. Pharm. Des. 10, 1567\u20131576 (2004).","journal-title":"Curr. Pharm. Des."},{"key":"511_CR87","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1046\/j.1365-2141.2000.02267.x","volume":"110","author":"A Szczeklik","year":"2000","unstructured":"Szczeklik, A., Undas, A., Sanak, M., Fro\u0142ow, M. & W\u0119grzyn, W. Relationship between bleeding time, aspirin and the PlA1\/A2 polymorphism of platelet glycoprotein IIIa. Br. J. Haematol. 110, 965\u2013967 (2000).","journal-title":"Br. J. Haematol."},{"key":"511_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49123-y","volume":"9","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Association among PlA1\/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis. Sci. Rep. 9, 13177 (2019).","journal-title":"Sci. Rep."},{"key":"511_CR89","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/MBC.0000000000000404","volume":"27","author":"E Derle","year":"2016","unstructured":"Derle, E. et al. Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. Blood Coagul. Fibrinolysis 27, 169\u2013175 (2016).","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"511_CR90","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/j.thromres.2010.01.011","volume":"125","author":"F Abderrazek","year":"2010","unstructured":"Abderrazek, F. et al. The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb. Res. 125, e265\u2013e268 (2010).","journal-title":"Thromb. Res."},{"key":"511_CR91","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1111\/j.1538-7836.2011.04482.x","volume":"9","author":"M Postula","year":"2011","unstructured":"Postula, M. et al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J. Thromb. Haemost. 9, 2291\u20132301 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"511_CR92","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/ng.604","volume":"42","author":"AD Johnson","year":"2010","unstructured":"Johnson, A. D. et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat. Genet. 42, 608\u2013613 (2010).","journal-title":"Nat. Genet."},{"key":"511_CR93","doi-asserted-by":"crossref","unstructured":"Bourgeois, S. et al. Genome-wide association between EYA1 and aspirin-induced peptic ulceration. EBioMedicine 74,103728 (2021).","DOI":"10.1016\/j.ebiom.2021.103728"},{"key":"511_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99402-w","volume":"11","author":"N Mallah","year":"2021","unstructured":"Mallah, N. et al. A multicenter case\u2013control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users. Sci. Rep. 11, 19923 (2021).","journal-title":"Sci. Rep."},{"key":"511_CR95","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/07853890.2021.2016940","volume":"54","author":"N Mallah","year":"2022","unstructured":"Mallah, N. et al. Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study. Ann. Med. 54, 379\u2013392 (2022).","journal-title":"Ann. Med."},{"key":"511_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.671835","volume":"12","author":"M Forgerini","year":"2021","unstructured":"Forgerini, M. et al. Genetic variants in PTGS1 and NOS3 genes increase the risk of upper gastrointestinal bleeding: A case\u2013control study. Front. Pharmacol. 12, 671835 (2021).","journal-title":"Front. Pharmacol."},{"key":"511_CR97","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.dld.2021.04.038","volume":"53","author":"Y Handa","year":"2021","unstructured":"Handa, Y. et al. A novel gene associated with small bowel bleeding in patients taking low-dose aspirin. Dig. Liver Dis. 53, 841\u2013845 (2021).","journal-title":"Dig. Liver Dis."},{"key":"511_CR98","doi-asserted-by":"crossref","unstructured":"Zeng, W. et al. Genetic factors related to aspirin resistance using the Multiplate\u00ae device in Hong Kong Chinese patients with stable coronary heart disease. Heliyon 10, e34552 (2024).","DOI":"10.1016\/j.heliyon.2024.e34552"},{"key":"511_CR99","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ijcard.2016.07.212","volume":"222","author":"X Humbert","year":"2016","unstructured":"Humbert, X. et al. Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease. Int. J. Cardiol. 222, 1079\u20131083 (2016).","journal-title":"Int. J. Cardiol."},{"key":"511_CR100","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1872312811206030002","volume":"6","author":"S-Y Kim","year":"2012","unstructured":"Kim, S.-Y. et al. Metabolism of R-and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab. Lett. 6, 157\u2013164 (2012).","journal-title":"Drug Metab. Lett."},{"key":"511_CR101","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","volume":"18","author":"JD Duarte","year":"2021","unstructured":"Duarte, J. D. & Cavallari, L. H. Pharmacogenetics to guide cardiovascular drug therapy. Nat. Rev. Cardiol. 18, 649\u2013665 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"511_CR102","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/cpt.558","volume":"101","author":"MJ Arwood","year":"2017","unstructured":"Arwood, M. J. et al. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: a proposal for a new pharmacogenetic dosing approach. Clin. Pharmacol. Ther. 101, 675\u2013683 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR103","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","volume":"102","author":"JA Johnson","year":"2017","unstructured":"Johnson, J. A. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin. Pharmacol. Ther. 102, 397\u2013404 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR104","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/cpt.2957","volume":"114","author":"A Oni-Orisan","year":"2023","unstructured":"Oni-Orisan, A. et al. An introductory tutorial on cardiovascular pharmacogenetics for healthcare providers. Clin. Pharmacol. Ther. 114, 275\u2013287 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR105","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jmoldx.2020.04.204","volume":"22","author":"VM Pratt","year":"2020","unstructured":"Pratt, V. M. et al. Recommendations for clinical warfarin genotyping allele selection: a report of the Association for Molecular Pathology and the College of American Pathologists. J. Mol. Diagn. 22, 847\u2013859 (2020).","journal-title":"J. Mol. Diagn."},{"key":"511_CR106","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.1182\/bloodadvances.2024014227","volume":"8","author":"IG Asiimwe","year":"2024","unstructured":"Asiimwe, I. G. et al. Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry. Blood Adv. 8, 5248\u20135261 (2024).","journal-title":"Blood Adv."},{"key":"511_CR107","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1179\/acb.2006.036","volume":"61","author":"P Verhamme","year":"2006","unstructured":"Verhamme, P. & Hoylaerts, M. F. The pivotal role of the endothelium in haemostasis and thrombosis.Acta Clinica Belgica 61, 213\u2013219 (2006).","journal-title":"Acta Clinica Belgica"},{"key":"511_CR108","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1517\/14728222.2015.1009446","volume":"19","author":"L Xu","year":"2015","unstructured":"Xu, L. et al. Caveolae: molecular insights and therapeutic targets for stroke. Expert Opin. Ther. Targets 19, 633\u2013650 (2015).","journal-title":"Expert Opin. Ther. Targets"},{"key":"511_CR109","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","volume":"111","author":"RM Cooper-DeHoff","year":"2022","unstructured":"Cooper-DeHoff, R. M. et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin. Pharmacol. Ther. 111, 1007\u20131021 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR110","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/07853890.2020.1800074","volume":"52","author":"N Ahangari","year":"2020","unstructured":"Ahangari, N. et al. Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy. Ann. Med. 52, 462\u2013470 (2020).","journal-title":"Ann. Med."},{"key":"511_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-016-0573-6","volume":"18","author":"JE Alfonsi","year":"2016","unstructured":"Alfonsi, J. E., Hegele, R. A. & Gryn, S. E. Pharmacogenetics of lipid-lowering agents: precision or indecision medicine?. Curr. Atheroscler. Rep. 18, 1\u201310 (2016).","journal-title":"Curr. Atheroscler. Rep."},{"key":"511_CR112","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clinbiochem.2007.03.016","volume":"40","author":"I Buhaescu","year":"2007","unstructured":"Buhaescu, I. & Izzedine, H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin. Biochem. 40, 575\u2013584 (2007).","journal-title":"Clin. Biochem."},{"key":"511_CR113","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40291-016-0238-8","volume":"21","author":"D Mitchell","year":"2017","unstructured":"Mitchell, D., Guertin, J. R., Iliza, A. C., Fanton-Aita, F. & LeLorier, J. Economic evaluation of a pharmacogenomics test for statin-induced myopathy in cardiovascular high-risk patients initiating a statin. Mol. Diagn. Ther. 21, 95\u2013105 (2017).","journal-title":"Mol. Diagn. Ther."},{"key":"511_CR114","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2217\/pgs.15.158","volume":"17","author":"M Leusink","year":"2016","unstructured":"Leusink, M., Onland-Moret, N. C., de Bakker, P. I., de Boer, A. & Maitland-van der Zee, A. H. Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics 17, 163\u2013180 (2016).","journal-title":"Pharmacogenomics"},{"key":"511_CR115","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.vph.2005.07.012","volume":"44","author":"G Schmitz","year":"2006","unstructured":"Schmitz, G. & Langmann, T. Pharmacogenomics of cholesterol-lowering therapy. Vasc. Pharmacol. 44, 75\u201389 (2006).","journal-title":"Vasc. Pharmacol."},{"key":"511_CR116","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bcp.12377","volume":"78","author":"T Prueksaritanont","year":"2014","unstructured":"Prueksaritanont, T. et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br. J. Clin. Pharmacol. 78, 587\u2013598 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"511_CR117","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/FPC.0000000000000148","volume":"25","author":"A Tornio","year":"2015","unstructured":"Tornio, A. et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenet. Genomics 25, 382\u2013387 (2015).","journal-title":"Pharmacogenet. Genomics"},{"key":"511_CR118","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"Group, S. C.","year":"2008","unstructured":"Group, S. C. SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N. Engl. J. Med. 359, 789\u2013799 (2008).","journal-title":"N. Engl. J. Med."},{"key":"511_CR119","doi-asserted-by":"publisher","first-page":"35669","DOI":"10.1074\/jbc.M103792200","volume":"276","author":"RG Tirona","year":"2001","unstructured":"Tirona, R. G., Leake, B. F., Merino, G. & Kim, R. B. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J. Biol. Chem. 276, 35669\u201335675 (2001).","journal-title":"J. Biol. Chem."},{"key":"511_CR120","doi-asserted-by":"publisher","first-page":"650","DOI":"10.4161\/cbt.4.6.1731","volume":"4","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom, A. et al. Effect of ABCG2 genotype on the oral vioavailability of topotecan. Cancer Biol. Ther. 4, 650\u2013653 (2005).","journal-title":"Cancer Biol. Ther."},{"key":"511_CR121","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.79","volume":"86","author":"J Keskitalo","year":"2009","unstructured":"Keskitalo, J. et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86, 197\u2013203 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR122","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","volume":"6","author":"MK DeGorter","year":"2013","unstructured":"DeGorter, M. K. et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ. Cardiovasc. Genet. 6, 400\u2013408 (2013).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"511_CR123","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/dmd.104.001628","volume":"33","author":"D Kobayashi","year":"2005","unstructured":"Kobayashi, D. et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos.33, 94\u2013101 (2005).","journal-title":"Drug Metab. Dispos."},{"key":"511_CR124","first-page":"611","volume":"1","author":"Y Imai","year":"2002","unstructured":"Imai, Y. et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther.1, 611\u2013616 (2002).","journal-title":"Mol. Cancer Ther."},{"key":"511_CR125","unstructured":"Cid-Conde, L. & L\u00f3pez-Castro, J. In Cardiovascular Risk Factors in Pathology (IntechOpen, 2020)."},{"key":"511_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-10-96","volume":"10","author":"G Jermendy","year":"2011","unstructured":"Jermendy, G. et al. Effect of genetic and environmental influences on cardiometabolic risk factors: a twin study. Cardiovasc. Diabetol. 10, 1\u20138 (2011).","journal-title":"Cardiovasc. Diabetol."},{"key":"511_CR127","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/MOL.0b013e32835cf284","volume":"24","author":"MW Medina","year":"2013","unstructured":"Medina, M. W. & Krauss, R. M. Alternative splicing in the regulation of cholesterol homeostasis. Curr. Opin. Lipidol. 24, 147\u2013152 (2013).","journal-title":"Curr. Opin. Lipidol."},{"key":"511_CR128","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.tcm.2009.10.003","volume":"19","author":"MW Medina","year":"2009","unstructured":"Medina, M. W. & Krauss, R. M. The role of HMGCR alternative splicing in statin efficacy. Trends Cardiovasc. Med. 19, 173\u2013177 (2009).","journal-title":"Trends Cardiovasc. Med."},{"key":"511_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0000000000000178","volume":"26","author":"V Leduc","year":"2016","unstructured":"Leduc, V., Bourque, L., Poirier, J. & Dufour, R. Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia. Pharmacogenet. Genomics 26, 1\u201311 (2016).","journal-title":"Pharmacogenet. Genomics"},{"key":"511_CR130","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.5603\/KP.2016.0157","volume":"74","author":"AL Catapano","year":"2016","unstructured":"Catapano, A. L. et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Pol. Heart J. 74, 1234\u20131318 (2016).","journal-title":"Pol. Heart J."},{"key":"511_CR131","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman, M. G. et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316, 1289\u20131297 (2016).","journal-title":"JAMA"},{"key":"511_CR132","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00439-007-0327-1","volume":"121","author":"H Muallem","year":"2007","unstructured":"Muallem, H. et al. Quantitative effects of common genetic variations in the 3\u2032 UTR of the human LDL-receptor gene and their associations with plasma lipid levels in the Atherosclerosis Risk in Communities study. Hum. Genet. 121, 421\u2013431 (2007).","journal-title":"Hum. Genet."},{"key":"511_CR133","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2007.12.004","volume":"200","author":"E Polisecki","year":"2008","unstructured":"Polisecki, E. et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 200, 109\u2013114 (2008).","journal-title":"Atherosclerosis"},{"key":"511_CR134","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3163\/1536-5050.102.3.017","volume":"102","author":"CD Adams","year":"2014","unstructured":"Adams, C. D. Stockley\u2019s drug interactions. Stockley\u2019s Drug Interactions Pocket Companion 2013. J. Med. Libr. Assoc.102, 221 (2014).","journal-title":"J. Med. Libr. Assoc."},{"key":"511_CR135","first-page":"100","volume":"1","author":"D Voora","year":"2008","unstructured":"Voora, D. et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circulation: Cardiovasc. Genet. 1, 100\u2013106 (2008).","journal-title":"Circulation: Cardiovasc. Genet."},{"key":"511_CR136","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2004.09.004","volume":"177","author":"K Kajinami","year":"2004","unstructured":"Kajinami, K., Takekoshi, N., Brousseau, M. E. & Schaefer, E. J. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 177, 219\u2013234 (2004).","journal-title":"Atherosclerosis"},{"key":"511_CR137","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/jcpt.12369","volume":"41","author":"P Kadam","year":"2016","unstructured":"Kadam, P., Ashavaid, T., Ponde, C. & Rajani, R. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J. Clin. Pharm. Ther. 41, 329\u2013333 (2016).","journal-title":"J. Clin. Pharm. Ther."},{"key":"511_CR138","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez, B. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 39, 119\u2013177 (2018).","journal-title":"Eur. Heart J."},{"key":"511_CR139","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fphys.2013.00265","volume":"4","author":"M Ciccarelli","year":"2013","unstructured":"Ciccarelli, M., Santulli, G., Pascale, V., Trimarco, B. & Iaccarino, G. Adrenergic receptors and metabolism: role in development of cardiovascular disease. Front. Physiol. 4, 265 (2013).","journal-title":"Front. Physiol."},{"key":"511_CR140","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","volume":"150","author":"FA McAlister","year":"2009","unstructured":"McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A. & Armstrong, P. W. Meta-analysis: \u03b2-blocker dose, heart rate reduction, and death in patients with heart failure. Ann. Intern. Med. 150, 784\u2013794 (2009).","journal-title":"Ann. Intern. Med."},{"key":"511_CR141","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/eurheartj\/ehn123","volume":"29","author":"R Kolloch","year":"2008","unstructured":"Kolloch, R. et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR\/trandolapril STudy (INVEST). Eur. Heart J. 29, 1327\u20131334 (2008).","journal-title":"Eur. Heart J."},{"key":"511_CR142","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10741-019-09825-x","volume":"25","author":"DC Ali","year":"2020","unstructured":"Ali, D. C. et al. \u03b2-Adrenergic receptor, an essential target in cardiovascular diseases. Heart Fail. Rev. 25, 343\u2013354 (2020).","journal-title":"Heart Fail. Rev."},{"key":"511_CR143","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.amjcard.2012.11.015","volume":"111","author":"V Cotarlan","year":"2013","unstructured":"Cotarlan, V., Brofferio, A., Gerhard, G. S., Chu, X. & Shirani, J. Impact of \u03b21-and \u03b22-adrenergic receptor gene single nucleotide polymorphisms on heart rate response to metoprolol prior to coronary computed tomographic angiography. Am. J. Cardiol. 111, 661\u2013666 (2013).","journal-title":"Am. J. Cardiol."},{"key":"511_CR144","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1006\/jmcc.2002.2033","volume":"34","author":"NN Petrashevskaya","year":"2002","unstructured":"Petrashevskaya, N. N., Koch, S. E., Bodi, I. & Schwartz, A. Calcium cycling, historic overview and perspectives. Role for autonomic nervous system regulation. J. Mol. Cell. Cardiol. 34, 885\u2013896 (2002).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"511_CR145","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1592\/phco.27.6.874","volume":"27","author":"J Shin","year":"2007","unstructured":"Shin, J. & Johnson, J. A. Pharmacogenetics of \u03b2-blockers. Pharmacotherapy 27, 874\u2013887 (2007).","journal-title":"Pharmacotherapy"},{"key":"511_CR146","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/jssc.201301353","volume":"37","author":"SH Bae","year":"2014","unstructured":"Bae, S. H., Lee, J. K., Cho, D. Y. & Bae, S. K. Simultaneous determination of metoprolol and its metabolites, \u03b1-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: A pplication to the pharmacokinetics of metoprolol associated with CYP 2 D 6 genotypes. J. Sep. Sci. 37, 1256\u20131264 (2014).","journal-title":"J. Sep. Sci."},{"key":"511_CR147","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/17425255.2020.1803279","volume":"16","author":"CD Thomas","year":"2020","unstructured":"Thomas, C. D. & Johnson, J. A. Pharmacogenetic factors affecting \u03b2-blocker metabolism and response. Expert Opin. Drug Metab. Toxicol. 16, 953\u2013964 (2020).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"511_CR148","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/clpt.2013.96","volume":"94","author":"CM Blake","year":"2013","unstructured":"Blake, C. M., Kharasch, E., Schwab, M. & Nagele, P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin. Pharmacol. Ther. 94, 394\u2013399 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR149","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2217\/pgs.11.20","volume":"12","author":"D Sehrt","year":"2011","unstructured":"Sehrt, D., Meineke, I., Tzvetkov, M., G\u00fcltepe, S. & Brockm\u00f6ller, J. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 12, 783\u2013795 (2011).","journal-title":"Pharmacogenomics"},{"key":"511_CR150","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/clpt.2014.62","volume":"96","author":"IS Hamadeh","year":"2014","unstructured":"Hamadeh, I. S. et al. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin. Pharmacol. Ther. 96, 175\u2013181 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR151","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/clpt.2013.193","volume":"95","author":"J Batty","year":"2014","unstructured":"Batty, J. et al. An investigation of CYP2D6 genotype and response to metoprolol CR\/XL during dose titration in patients with heart failure: a MERIT-HF substudy. Clin. Pharmacol. Ther.95, 321\u2013330 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR152","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1177\/147323000803600624","volume":"36","author":"H Yuan","year":"2008","unstructured":"Yuan, H. et al. Effects of polymorphism of the \u03b21 adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol. J. Int. Med. Res. 36, 1354\u20131362 (2008).","journal-title":"J. Int. Med. Res."},{"key":"511_CR153","doi-asserted-by":"crossref","unstructured":"Lymperopoulos, A. & French, F. Pharmacogenomics of heart failure. Methods Mol. Biol. 1175, 245\u2013257 (2014).","DOI":"10.1007\/978-1-4939-0956-8_10"},{"key":"511_CR154","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/clpt.2012.18","volume":"92","author":"T Rau","year":"2012","unstructured":"Rau, T. et al. Impact of the \u03b21-adrenoceptor Arg389Gly polymorphism on heart-rate responses to Bisoprolol and carvedilol in heart-failure patients. Clin. Pharmacol. Ther. 92, 21\u201328 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR155","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/sj.bjp.0705753","volume":"142","author":"S Joseph","year":"2004","unstructured":"Joseph, S., Lynham, J., Grace, A., Colledge, W. & Kaumann, A. Markedly reduced effects of (\u2212)-isoprenaline but not of (\u2212)-CGP12177 and unchanged affinity of \u03b2-blockers at Gly389-\u03b21-adrenoceptors compared to Arg389-\u03b21-adrenoceptors. Br. J. Pharmacol. 142, 51\u201356 (2004).","journal-title":"Br. J. Pharmacol."},{"key":"511_CR156","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1056\/NEJMoa010819","volume":"345","author":"V Dishy","year":"2001","unstructured":"Dishy, V. et al. The effect of common polymorphisms of the \u03b22-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345, 1030\u20131035 (2001).","journal-title":"N. Engl. J. Med."},{"key":"511_CR157","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1165\/ajrcmb.13.1.7598936","volume":"13","author":"SA Green","year":"1995","unstructured":"Green, S. A., Turki, J., Bejarano, P., Hall, I. P. & Liggett, S. B. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 13, 25\u201333 (1995).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"511_CR158","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41421-018-0058-6","volume":"4","author":"J Huang","year":"2018","unstructured":"Huang, J. et al. ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to \u03b2-blockers in patients with heart failure. Cell Discov. 4, 57 (2018).","journal-title":"Cell Discov."},{"key":"511_CR159","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.2217\/pgs.09.92","volume":"10","author":"D Kurnik","year":"2009","unstructured":"Kurnik, D. et al. GRK5 Gln41Leu polymorphism is not associated with sensitivity to \u03b21-adrenergic blockade in humans. Pharmacogenomics 10, 1581\u20131587 (2009).","journal-title":"Pharmacogenomics"},{"key":"511_CR160","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nm1750","volume":"14","author":"SB Liggett","year":"2008","unstructured":"Liggett, S. B. et al. A GRK5 polymorphism that inhibits \u03b2-adrenergic receptor signaling is protective in heart failure. Nat. Med. 14, 510\u2013517 (2008).","journal-title":"Nat. Med."},{"key":"511_CR161","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/46040","volume":"402","author":"L Hein","year":"1999","unstructured":"Hein, L., Altman, J. D. & Kobilka, B. K. Two functionally distinct \u03b12-adrenergic receptors regulate sympathetic neurotransmission. Nature 402, 181\u2013184 (1999).","journal-title":"Nature"},{"key":"511_CR162","doi-asserted-by":"publisher","first-page":"23059","DOI":"10.1074\/jbc.M000796200","volume":"275","author":"KM Small","year":"2000","unstructured":"Small, K. M., Forbes, S. L., Rahman, F. F., Bridges, K. M. & Liggett, S. B. A four amino acid deletion polymorphism in the third intracellular loop of the human \u03b12C-adrenergic receptor confers impaired coupling to multiple effectors. J. Biol. Chem. 275, 23059\u201323064 (2000).","journal-title":"J. Biol. Chem."},{"key":"511_CR163","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01213011-200503000-00002","volume":"15","author":"A Neumeister","year":"2005","unstructured":"Neumeister, A. et al. Sympathoneural and adrenomedullary functional effects of \u03b12C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet. Genomics 15, 143\u2013149 (2005).","journal-title":"Pharmacogenet. Genomics"},{"key":"511_CR164","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/cpt.3351","volume":"116","author":"JD Duarte","year":"2024","unstructured":"Duarte, J. D. et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and beta-blocker therapy. Clin. Pharmacol. Ther. 116, 939\u2013947 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"511_CR165","doi-asserted-by":"publisher","first-page":"e0224858","DOI":"10.1371\/journal.pone.0224858","volume":"14","author":"HA Ali","year":"2019","unstructured":"Ali, H. A. et al. Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: a systematic review and evaluation of methodological approaches. PLoS ONE 14, e0224858 (2019).","journal-title":"PLoS ONE"},{"key":"511_CR166","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/cea.13326","volume":"49","author":"Y Liau","year":"2019","unstructured":"Liau, Y., Chua, I., Kennedy, M. A. & Maggo, S. Pharmacogenetics of angiotensin-converting enzyme inhibitor-induced angioedema. Clin. Exp. Allergy 49, 142\u2013154 (2019).","journal-title":"Clin. Exp. Allergy"},{"key":"511_CR167","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10557-017-6733-2","volume":"31","author":"HK Flaten","year":"2017","unstructured":"Flaten, H. K. & Monte, A. A. The pharmacogenomic and metabolomic predictors of ACE inhibitor and angiotensin II receptor blocker effectiveness and safety. Cardiovasc. Drugs Ther. 31, 471\u2013482 (2017).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"511_CR168","first-page":"3","volume":"2","author":"B Ollomo","year":"2019","unstructured":"Ollomo, B. et al. D Allele and DD genotype of i\/d polymorphism in the ace gene in patients with hypertension, stroke and cancer prostate in libreville: a concern given the high frequencies of these signatures in gabonese population I\/D polymorphism in the ACE gene in patients with hypertension, stroke and cancer prostate in Libreville: a concern given the high frequencies of these signatures in Gabonese population. J. Proteom. Genomics Res. 2, 3 (2019).","journal-title":"J. Proteom. Genomics Res."},{"key":"511_CR169","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/01.CIR.90.2.669","volume":"90","author":"F Cambien","year":"1994","unstructured":"Cambien, F. et al. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 90, 669\u2013676 (1994).","journal-title":"Circulation"},{"key":"511_CR170","doi-asserted-by":"publisher","first-page":"531","DOI":"10.5858\/2000-124-0531-ACEPAT","volume":"124","author":"N Dzimiri","year":"2000","unstructured":"Dzimiri, N., Basco, C., Moorji, A. & Meyer, B. F. Angiotensin-converting enzyme polymorphism and the risk of coronary heart disease in the Saudi male population. Arch. Pathol. Lab. Med. 124, 531\u2013534 (2000).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"511_CR171","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40615-020-00853-0","volume":"8","author":"R Sarangarajan","year":"2021","unstructured":"Sarangarajan, R. et al. Ethnic prevalence of angiotensin-converting enzyme deletion (D) polymorphism and COVID-19 risk: rationale for use of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers. J. Racial Ethn. Health Disparities 8, 973\u2013980 (2021).","journal-title":"J. Racial Ethn. Health Disparities"},{"key":"511_CR172","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/979631","volume":"2015","author":"D Tchelougou","year":"2015","unstructured":"Tchelougou, D. et al. Renin-angiotensin system genes polymorphisms and essential hypertension in Burkina Faso, West Africa. Int. J. Hypertens. 2015, 979631 (2015).","journal-title":"Int. J. Hypertens."},{"key":"511_CR173","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/sj.jhh.1000958","volume":"14","author":"E Martinez","year":"2000","unstructured":"Martinez, E. et al. Angiotensin-converting enzyme (ACE) gene polymorphisms, serum ACE activity and blood pressure in a Spanish-Mediterranean population. J. Hum. Hypertens. 14, 131\u2013135 (2000).","journal-title":"J. Hum. Hypertens."},{"key":"511_CR174","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s10528-015-9706-9","volume":"54","author":"S Baruah","year":"2016","unstructured":"Baruah, S. et al. Insertion\/insertion genotype of angiotensin i-converting-enzyme gene predicts risk of myocardial infarction in North East India. Biochem. Genet. 54, 134\u2013146 (2016).","journal-title":"Biochem. Genet."},{"key":"511_CR175","doi-asserted-by":"publisher","first-page":"8068","DOI":"10.4238\/2015.July.17.15","volume":"14","author":"W Zhao","year":"2015","unstructured":"Zhao, W., Ma, S. & Cui, L. Meta-analysis of angiotensin-converting enzyme insertion\/deletion polymorphism and myocardial infarction in Han Chinese. Genet. Mol. Res. 14, 8068\u20138076 (2015).","journal-title":"Genet. Mol. Res."},{"key":"511_CR176","doi-asserted-by":"publisher","first-page":"142","DOI":"10.18433\/jpps30339","volume":"22","author":"MD Pjevi\u0107","year":"2019","unstructured":"Pjevi\u0107, M. D. et al. Analysis of the association between polymorphisms within PAI-1 and ACE genes and ischemic stroke outcome after rt-PA therapy. J. Pharm. Pharm. Sci. 22, 142\u2013149 (2019).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"511_CR177","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/00207454.2017.1412962","volume":"128","author":"RG Malueka","year":"2018","unstructured":"Malueka, R. G. et al. The D allele of the angiotensin-converting enzyme (ACE) insertion\/deletion (I\/D) polymorphism is associated with worse functional outcome of ischaemic stroke. Int. J. Neurosci. 128, 697\u2013704 (2018).","journal-title":"Int. J. Neurosci."},{"key":"511_CR178","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.mgene.2014.09.003","volume":"2","author":"M Vijayan","year":"2014","unstructured":"Vijayan, M. et al. ACE-II genotype and I allele predicts ischemic stroke among males in south India. Meta Gene 2, 661\u2013669 (2014).","journal-title":"Meta Gene"},{"key":"511_CR179","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0092-8674(92)90275-H","volume":"71","author":"X Jeunemaitre","year":"1992","unstructured":"Jeunemaitre, X. et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 71, 169\u2013180 (1992).","journal-title":"Cell"},{"key":"511_CR180","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/metabo12121291","volume":"12","author":"M Shahid","year":"2022","unstructured":"Shahid, M. et al. Genetic polymorphism in angiotensinogen and its association with cardiometabolic diseases. Metabolites 12, 1291 (2022).","journal-title":"Metabolites"},{"key":"511_CR181","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0895-7061(99)00006-0","volume":"12","author":"J-R Jeng","year":"1999","unstructured":"Jeng, J.-R. Left ventricular mass, carotid wall thickness, and angiotensinogen gene polymorphism in patients with hypertension. Am. J. Hypertens.12, 443\u2013450 (1999).","journal-title":"Am. J. Hypertens."},{"key":"511_CR182","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/01.HYP.38.1.110","volume":"38","author":"R Schmidt","year":"2001","unstructured":"Schmidt, R. et al. Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities. Hypertension 38, 110\u2013115 (2001).","journal-title":"Hypertension"},{"key":"511_CR183","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1097\/01.hjh.0000173510.52987.68","volume":"23","author":"PB Mellen","year":"2005","unstructured":"Mellen, P. B. & Herrington, D. M. Pharmacogenomics of blood pressure response to antihypertensive treatment. J. Hypertens. 23, 1311\u20131325 (2005).","journal-title":"J. Hypertens."},{"key":"511_CR184","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.608948","volume":"8","author":"TT Tran","year":"2021","unstructured":"Tran, T. T. et al. Association between AGT M235T and left ventricular mass in Vietnamese patients diagnosed with essential hypertension. Front. Cardiovasc. Med. 8, 608948 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"511_CR185","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/07853899708998740","volume":"29","author":"K Helin","year":"1997","unstructured":"Helin, K., Stoll, M., Meffert, S., Stroth, U. & Linger, T. The role of angiotensin receptors in cardiovascular diseases. Ann. Med. 29, 23\u201329 (1997).","journal-title":"Ann. Med."},{"key":"511_CR186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12920-018-0427-x","volume":"11","author":"P Kontou","year":"2018","unstructured":"Kontou, P. et al. Identification of gene expression profiles in myocardial infarction: a systematic review and meta-analysis. BMC Med. Genomics 11, 1\u201311 (2018).","journal-title":"BMC Med. Genomics"},{"key":"511_CR187","first-page":"477","volume":"11","author":"GK Andrikopoulos","year":"2004","unstructured":"Andrikopoulos, G. K. et al. The paradoxical association of common polymorphisms of the renin-angiotensin system genes with risk of myocardial infarction. Eur. J. Cardiovasc. Prev. Rehabil. 11, 477\u2013483 (2004).","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"511_CR188","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1590\/S0066-782X2004001700007","volume":"83","author":"MA de Ara\u00fajo","year":"2004","unstructured":"de Ara\u00fajo, M. A. et al. The A1166C polymorphism of the angiotensin II type-1 receptor in acute myocardial infarction. Arq. Bras. Cardiol. 83, 404\u2013408 (2004).","journal-title":"Arq. Bras. Cardiol."},{"key":"511_CR189","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3390\/genes13071257","volume":"13","author":"I Gor\u0105cy","year":"2022","unstructured":"Gor\u0105cy, I. et al. The genetic variants in the renin-angiotensin system and the risk of heart failure in polish patients. Genes 13, 1257 (2022).","journal-title":"Genes"},{"key":"511_CR190","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1291\/hypres.25.515","volume":"25","author":"Y Liu","year":"2002","unstructured":"Liu, Y. et al. A1166C polymorphism of the angiotensin II type 1 receptor gene and essential hypertension in Han, Tibetan and Yi populations. Hypertens. Res. 25, 515\u2013521 (2002).","journal-title":"Hypertens. Res."},{"key":"511_CR191","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00043798-199710000-00013","volume":"4","author":"JA Staessen","year":"1997","unstructured":"Staessen, J. A. et al. Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J. Cardiovasc. Risk4, 401\u2013422 (1997).","journal-title":"J. Cardiovasc. Risk"},{"key":"511_CR192","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.tpj.6500215","volume":"4","author":"L Frazier","year":"2004","unstructured":"Frazier, L., Turner, S., Schwartz, G., Chapman, A. & Boerwinkle, E. Multilocus effects of the renin\u2013angiotensin\u2013aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J. 4, 17\u201323 (2004).","journal-title":"Pharmacogenomics J."},{"key":"511_CR193","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1161\/CIRCULATIONAHA.106.642058","volume":"115","author":"X Su","year":"2007","unstructured":"Su, X. et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 115, 725\u2013732 (2007).","journal-title":"Circulation"},{"key":"511_CR194","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/FPC.0b013e328348c6db","volume":"21","author":"S Mas","year":"2011","unstructured":"Mas, S. et al. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of: ACE:: ABO:, and: BDKRB2: genes. Pharmacogenet. Genomics 21, 531\u2013538 (2011).","journal-title":"Pharmacogenet. Genomics"},{"key":"511_CR195","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/tpj.2015.51","volume":"16","author":"JD Mosley","year":"2016","unstructured":"Mosley, J. D. et al. A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. Pharmacogenomics J. 16, 231\u2013237 (2016).","journal-title":"Pharmacogenomics J."},{"key":"511_CR196","doi-asserted-by":"crossref","unstructured":"Strunk, R. C. Integration of mouse and human genome-wide association data identifies KCNIP4 as an asthma gene. PLoS ONE 8, e56179 (2013).","DOI":"10.1371\/journal.pone.0056179"},{"key":"511_CR197","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/FPC.0b013e328363c137","volume":"23","author":"G Pare","year":"2013","unstructured":"Pare, G. et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet. Genomics 23, 470\u2013478 (2013).","journal-title":"Pharmacogenet. Genomics"}],"container-title":["npj Genomic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00511-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T07:58:10Z","timestamp":1757231890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00511-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":197,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1038\/s41525-025-00511-6","relation":{},"ISSN":["2056-7944"],"issn-type":[{"value":"2056-7944","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no potential conflicts of interest. Although Prof. Muhammad Abu-Elmagd serves as an editor at npj Genomic Medicine, he was not involved in any stage of the peer review or editorial process related to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}